PriceTargets.com logo

ProQR Therapeutics - PRQR Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $6.80
  • Forecasted Upside: 323.68%
  • Number of Analysts: 8
  • Breakdown:
  • 1 Sell Ratings
  • 1 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$1.61 As of 03/19/2026 02:45 PM ET
▼ -0.115 (-6.69%)

This chart shows the closing price for PRQR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New ProQR Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PRQR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PRQR

Analyst Price Target is $6.80
▲ +323.68% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for ProQR Therapeutics in the last 3 months. The average price target is $6.80, with a high forecast of $9.00 and a low forecast of $4.00. The average price target represents a 323.68% upside from the last price of $1.61.

This chart shows the closing price for PRQR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 8 polled investment analysts is to moderate buy stock in ProQR Therapeutics. This rating has held steady since September 2025, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/25/2024
  • 1 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/24/2024
  • 1 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/24/2025
  • 1 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/22/2025
  • 1 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/20/2025
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
12/19/2025
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
2/17/2026
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
3/19/2026

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
3/13/2026CitigroupReiterated RatingMarket Outperform ➝ Market Outperform
3/12/2026OppenheimerInitiated CoverageOutperform$9.00
1/22/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
11/13/2025Zacks ResearchUpgradeStrong Sell ➝ Hold
11/4/2025Chardan CapitalReiterated RatingBuy ➝ Buy$4.00
10/15/2025Zacks ResearchDowngradeHold ➝ Strong Sell
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
8/8/2025Chardan CapitalReiterated RatingBuy ➝ Buy$4.00
7/11/2025EvercoreReiterated RatingOutperform ➝ Outperform
6/27/2025Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$8.00
6/27/2025Citizens JmpReiterated RatingMarket Outperform ➝ Market Outperform$8.00
5/13/2025OppenheimerLower TargetOutperform ➝ Outperform$15.00 ➝ $9.00
4/29/2025Cantor FitzgeraldInitiated CoverageOverweight$8.00
4/29/2025EvercoreInitiated CoverageOutperform$5.00
3/14/2025HC WainwrightBoost TargetBuy ➝ Buy$10.00 ➝ $12.00
3/14/2025Chardan CapitalReiterated RatingBuy ➝ Buy$4.00 ➝ $4.00
3/10/2025CitigroupUpgradeNeutral ➝ Buy$4.00
1/10/2025OppenheimerInitiated CoverageOutperform$15.00
12/12/2024Citizens JmpReiterated RatingMarket Outperform ➝ Market Outperform$8.00 ➝ $8.00
12/12/2024HC WainwrightReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
12/12/2024Chardan CapitalReiterated RatingBuy ➝ Buy$4.00 ➝ $4.00
11/8/2024HC WainwrightBoost TargetBuy ➝ Buy$5.00 ➝ $10.00
10/29/2024Raymond James FinancialUpgradeOutperform ➝ Strong-Buy$6.00 ➝ $14.00
5/10/2024Chardan CapitalReiterated RatingBuy ➝ Buy$2.50 ➝ $2.50
5/10/2024HC WainwrightReiterated RatingBuy ➝ Buy$5.00
4/18/2024CitigroupBoost TargetBuy ➝ Buy$1.80 ➝ $2.00
3/14/2024Chardan CapitalBoost TargetBuy ➝ Buy$2.00 ➝ $2.50
3/14/2024HC WainwrightReiterated RatingBuy ➝ Buy$5.00
11/8/2023Raymond James FinancialLower TargetOutperform ➝ Outperform$5.00 ➝ $4.00
11/8/2023Chardan CapitalUpgradeNeutral ➝ Buy$2.00
9/18/2023CitigroupLower TargetBuy ➝ Buy$2.10 ➝ $1.80
8/7/2023HC WainwrightReiterated RatingBuy ➝ Buy$5.00
8/4/2023Chardan CapitalReiterated RatingNeutral ➝ Neutral$2.00
5/17/2023Cantor FitzgeraldLower Target$5.00 ➝ $4.50
4/7/2023CitigroupLower Target$3.00 ➝ $2.25
3/30/2023HC WainwrightBoost TargetBuy$1.50 ➝ $5.00
3/30/2023Citizens JmpUpgradeMarket Perform ➝ Outperform$1.50 ➝ $5.00
12/23/2022Raymond James FinancialBoost TargetOutperform$2.00 ➝ $5.00
12/22/2022Cantor FitzgeraldUpgradeNeutral ➝ Overweight$5.00
8/15/2022Cantor FitzgeraldDowngradeOverweight ➝ Neutral
8/12/2022Raymond James FinancialUpgradeMarket Perform ➝ Outperform$2.00
8/12/2022Chardan CapitalDowngradeBuy ➝ Neutral
5/9/2022Cantor FitzgeraldReiterated RatingOverweight
5/9/2022HC WainwrightLower Target$4.00 ➝ $2.00
4/19/2022Cantor FitzgeraldLower Target$6.00 ➝ $3.50
4/14/2022Citizens JmpLower TargetMarket Outperform$8.00 ➝ $5.00
4/14/2022Chardan CapitalLower TargetBuy$8.00 ➝ $2.50
2/14/2022Chardan CapitalLower TargetBuy$18.00 ➝ $8.00
2/14/2022Citizens JmpLower TargetMarket Outperform$29.00 ➝ $8.00
2/14/2022HC WainwrightLower TargetBuy$20.00 ➝ $4.00
2/13/2022CitigroupDowngradeBuy ➝ Hold
2/11/2022Raymond James FinancialDowngradeStrong-Buy ➝ Market Perform
2/11/2022Stifel NicolausDowngradeBuy ➝ Hold$20.00 ➝ $3.00
2/1/2022Raymond James FinancialInitiated CoverageStrong-Buy$19.00
11/7/2021EvercoreReiterated RatingBuy$17.00
10/18/2021Cantor FitzgeraldReiterated RatingOverweight
9/30/2021Citizens JmpReiterated RatingBuy$31.00
9/12/2021EvercoreReiterated RatingBuy
9/10/2021Chardan CapitalReiterated RatingBuy$18.00
9/9/2021HC WainwrightReiterated RatingBuy$20.00
9/9/2021Citizens JmpReiterated RatingBuy$31.00
8/9/2021Chardan CapitalLower TargetBuy$20.00 ➝ $18.00
5/3/2021Stifel NicolausInitiated CoverageBuy$20.00
3/25/2021CitigroupBoost Target$33.00 ➝ $44.00
3/24/2021Cantor FitzgeraldBoost TargetPositive ➝ Overweight$22.00 ➝ $33.00
3/24/2021Citizens JmpBoost TargetOutperform$19.00 ➝ $35.00
(Data available from 3/19/2021 forward)

News Sentiment Rating

0.33 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/21/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/20/2025
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/20/2025
  • 0 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/19/2025
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/19/2025
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/18/2026
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/17/2026
  • 4 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
3/19/2026

Current Sentiment

  • 4 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

ProQR Therapeutics logo
ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.
Read More

Today's Range

Now: $1.61
Low: $1.59
High: $1.69

50 Day Range

MA: $1.62
Low: $1.39
High: $2.10

52 Week Range

Now: $1.61
Low: $1.07
High: $3.10

Volume

130,565 shs

Average Volume

402,941 shs

Market Capitalization

$169.10 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.21

Frequently Asked Questions

What sell-side analysts currently cover shares of ProQR Therapeutics?

The following sell-side analysts have issued research reports on ProQR Therapeutics in the last year: Cantor Fitzgerald, Chardan Capital, Citigroup Inc., Citizens Jmp, Evercore Inc, Oppenheimer Holdings, Inc., Wall Street Zen, Weiss Ratings, and Zacks Research.
View the latest analyst ratings for PRQR.

What is the current price target for ProQR Therapeutics?

0 Wall Street analysts have set twelve-month price targets for ProQR Therapeutics in the last year. Their average twelve-month price target is $6.80, suggesting a possible upside of 323.7%. Oppenheimer Holdings, Inc. has the highest price target set, predicting PRQR will reach $9.00 in the next twelve months. Chardan Capital has the lowest price target set, forecasting a price of $4.00 for ProQR Therapeutics in the next year.
View the latest price targets for PRQR.

What is the current consensus analyst rating for ProQR Therapeutics?

ProQR Therapeutics currently has 1 sell rating, 1 hold rating and 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for PRQR.

What other companies compete with ProQR Therapeutics?

Other companies that are similar to ProQR Therapeutics include Gyre Therapeutics, SELLAS Life Sciences Group, Theravance Biopharma, Bright Minds Biosciences and Alto Neuroscience. Learn More about companies similar to ProQR Therapeutics.

How do I contact ProQR Therapeutics' investor relations team?

ProQR Therapeutics' physical mailing address is Zernikedreef 9, Leiden P7, 2333 CK. The biopharmaceutical company's listed phone number is (188) 166-7000 and its investor relations email address is [email protected]. The official website for ProQR Therapeutics is www.proqr.com. Learn More about contacing ProQR Therapeutics investor relations.